Friday, March 01, 2024 10:12:46 AM
https://www.accesswire.com/838150/mres-m2bio-sciences-provides-corporate-update
If all preferred shares are converted into common shares, MRES is projected to hold approximately 71% of RLAB's fully diluted shares, with an expected total of 56,368,000 outstanding shares. As a result, investors can gain exposure to RLAB either directly or by holding shares in MRES.
So MRES holders would have around 40m shares of RLAB. So about 1 share for every 60 shares of MRES? That's just based on OS of 2,371,424,113 divided by 40 million is around 60.
Just off the top of my head......buying 100k of MRES here at .0085($850) gets you 1,666 shares of RLAB trading at .20($333).
kt
Recent MRES News
- M2Bio Sciences Appoints Adrian J. Maizey, Accomplished CEO and Financial Expert, to Advisory Board • InvestorsHub NewsWire • 07/19/2023 01:18:56 PM
- M2Bio Sciences Unveils an Exciting Line of Purple, White, and Green Teas from Kenya, Offering Extraordinary Health and Medicinal Benefits • InvestorsHub NewsWire • 07/14/2023 12:52:00 PM
- M2Bio Sciences Unveils Explainer Video Showcasing Groundbreaking NFTs and Altcoins for Drug Discovery, Revolutionizing Investment Access • InvestorsHub NewsWire • 07/06/2023 01:38:23 PM
- Institute of Biomedical Research Announces Application for Name Change and New Ticker Symbol in Anticipation of Future M&A Activities and Senior Listing • InvestorsHub NewsWire • 07/05/2023 02:04:17 PM
- M2Bio Sciences Enters into Letter of Intent to Acquire Crypto Exchange JDAX • InvestorsHub NewsWire • 06/26/2023 12:45:19 PM
- M2Bio Sciences Establishes Research Chair at The University of Pretoria for Phytomedicines • InvestorsHub NewsWire • 06/16/2023 12:30:00 PM
- M2Enviro Expands R&D Efforts to Explore Diverse Classes of Mycelium Composite Materials for Commercialization • InvestorsHub NewsWire • 06/14/2023 12:00:00 PM
- Institute of Biomedical Research unveils artificial intelligence (AI) powered initiatives within its CBD product range, psilocybin research, and cardiometabolic health solutions • InvestorsHub NewsWire • 06/07/2023 02:06:41 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM